Shore Capital retained AstraZeneca PLC (LON:AZN) to Sell in a report released today.
- Updated: March 20, 2017
Yesterday AstraZeneca PLC (LON:AZN) traded 0.64% higher at 4,870.00GBX. The company’s 50-day moving average is 4,590.99GBX and its 200-day moving average is 4,607.83GBX. The last closing price is up 6.28% from the 200-day moving average, compared to the S&P 500 which has increased 0.04% over the same time. 4,469,010 shares of the stock were exchanged, up from an average trading volume of 2,765,280
Shore Capital has retained AstraZeneca PLC (LON:AZN) to Sell in a report released on 03/20/2017.
Previously on 3/17/2017, Liberum Capital reported on AstraZeneca PLC (LON:AZN) held steady the target price at 5,100.00GBX. At the time, this indicated a possible upside of 0.06%.
See Chart Below
AstraZeneca PLC has a 52 week low of 3,680.00GBX and a 52 week high of 5,505.00GBX with a P/E ratio of 17.74 The company’s market cap is currently 0 GBX.
Also covering AstraZeneca PLC's price target, a total of 29 analysts have released a report on AstraZeneca PLC. The 12-month price target is 61.96GBX with 4 brokerages rating the stock a strong buy, 14 brokerages rating the stock a buy, 13 brokerages rating the stock a hold, 2 brokerages rating the stock a underperform, and finally one equity analyst rating the company a sell.
More About AstraZeneca PLC (LON:AZN)
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. The Company has its operations in over 100 countries. The Company's pipeline includes over 150 projects of which approximately 125 are in the clinical phase of development. The Company is developing a Toll-like receptor 9 (TLR-9) receptor agonist aimed at producing long-term benefit in asthma by addressing imbalances in the immune system. AstraZeneca offers various products, including Accolate, Rhinocort, Bricanyl Turbuhaler, Rhinocort, Symbicort pMDI, Crestor, Seloken/Toprol-XL, Brilinta/Brilique (ticagrelor), Bydureon, Xigduo XR, Kombiglyze XR and metformin XR, among others.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.